Company History

Foundation of Lonza AG Electricity Works in Gampel, Valais (Switzerland), on the banks of river Lonza. The electricity was used to manufacture calcium carbide and acetylene.

1909

Lonza moves to Visp and manufactures synthetic fertilizers out of nitrogen, ammonia and calcium carbide. Production
of nitric acid begins.

1947

Production
of ketene and diketene starts.

1965

Change of the raw material base from carbide to naphtha and further development of backwards integration: intermediates and additives for pharmaceuticals, agrochemicals, dyestuffs, colours, adhesives, etc.

1969

Lonza expands to the USA and starts its business with chemical specialties.

1971

Start of production of niacin, a vitamin of the B-group.

1974

Merger with Alusuisse and development into an internationally operating enterprise.

1980

Lonza starts its biotechnological business.

1982

Start of exclusive manufacturing of substances for pharmaceutical and agrochemical companies.

1992

Lonza acquires a biotechnological production facility (fermentation) in the Czech Republic.

1996

In Guangzhou
(CN) a joint venture is signed to build up a niacinamide plant primarily to satisfy
the regional market needs.

Lonza acquires Celltech Biologics (UK
and USA) and expands into the business with mammalian cell cultures and monoclonal
antibodies.

1999

Lonza is de-merged from the Alusuisse-Lonza
Group and listed as an independent company at the Swiss stock exchange.

2004

Lonza starts up three 20,000-liter
mammalian cell culture fermentation reactors in Portsmouth, NH (USA), the biggest
single investment in its history.

2005

Lonza announces a significant investment
program in the expansion of its peptides manufacturing capacities in its production
site in Visp (CH).

2006

Lonza
carries out a series of strategic transactions aimed at transforming the company
into one of the world’s leading suppliers of active pharmaceutical ingredients,
biopharmaceuticals and research products to the pharmaceutical, healthcare and life-science
industries.

Acquisition
of Bioproducts manufacturing division of UCB (Braine-L’Alleud, BE) positions Lonza
as a leading global provider of peptides to the biopharmaceutical market.

The fourth 20’000-liter bioreactor in Portsmouth, NH (USA) came on stream.

Lonza
announces the acquisition of the complementary Bioproducts and Biopharma businesses
from Cambrex to further enhance Lonza’s capability to service the needs of the high-growth
life sciences R&D and pharmaceutical development industries. The acquisition
also expands Lonza’s geographical footprint, particularly in the United States.

Agreement
with Genentech, one of the world’s largest biotechnology companies, to acquire mid-scale
biopharmaceutical manufacturing operation in Porriño (ES), providing significant
manufacturing capacity two years earlier than planned. In addition, Lonza will build
and start up a large-scale mammalian biopharmaceutical facility in Singapore, which
Genentech will have an exclusive option to buy upon U.S. FDA licensure. In parallel,
Lonza will build its own planned large-scale (4 x 20,000-liter) biopharmaceutical
manufacturing facility in Singapore.

2007

Lonza
announced that it has completed the acquisition of the Research Bioproducts business
and the Microbial Biopharmaceutical business of the U.S. company Cambrex, published
in October 2006.

Lonza
announced the acquisition of the assets of S.A.M. Electron Technologies based in
Shawinigan (CA). The acquisition of these assets is concurrent with an exclusive
worldwide license for a cerium mediator electrochemical technology (CeTECH™) from
Hydro-Québec and lease agreement with the City of Shawinigan.

Lonza
finalizes the divestiture of its purified isophthalic acid plant in Singapore.

2008

Lonza finalizes the selling of the majority of its shares in Polynt S.p.A.

Lonza
completes the acquisition of amaxa. The acquisition of amaxa is in line with Lonza’s
strategy of growing its life-science platform. amaxa is a premium supplier to the
cell discovery market with leading edge, proprietary technologies in well-defined
market niches of transfection systems.

2009

Teva and Lonza announced their agreement
to establish a joint venture to develop, manufacture and market a portfolio of
biosimilars.

Lonza expands its capacities for Carnipure™
and Carniking™ by investing in a new manufacturing facility for L-carnitine products
in Nansha (CN).

Lonza invests in new plant for vitamin
B3 (nicotinates) in Nansha (CN).

Lonza
Group Ltd acquires MODA Technology Partners, a software company that provides paperless
quality control solutions. The acquisition will strengthen the Rapid Testing Solutions
platform of Lonza’s Bioscience division by adding a complementary product offering
for quality assurance (QA) and quality control (QC) organizations in the life-science
industry.

Lonza
signs agreement with GlaxoSmithKline (GSK) to secure capacity and expertise in biological
manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio.
Thereby, Lonza will supply manufacturing capacity for five early-stage monoclonal
antibodies.

Lonza
acquires biotech service provider Algonomics, a contract research organization providing
integrated immunogenicity prediction services to support companies in the development
of biotherapeutics.

2011

Lonza
invests £16 million to further develop the flexibility and capability of its Slough
(UK) biopharmaceutical manufacturing facility to respond to a broader range of customer
projects and strengthen its global network of biologics development and manufacturing.

Lonza
plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in
Visp (CH) to serve growing oncology API market. Cytotoxic APIs are commonly used
in oncology therapeutics, which represent one of the fastest-growing segments of
the pharma and biotech industry.

Lonza
expands its viral-based therapeutics business with the construction of a new, state-of-the-art
cGMP clean room located adjacent to its existing Houston, TX (USA) operations.

Lonza
is investing CHF 10 million to expand its biopharmaceutical development services
platform in Singapore (SG) to meet increasing demand for biopharma development services
from preclinical to commercial.

Lonza
invests CHF 5.8 million in a formulation plant for Meta™ metaldehyde to enable Lonza
to supply its own formulations and allow the company to serve the market not only
with metaldehyde as an active substance, but also with ready-made slug pellets.

Lonza
celebrates 40 years as leading producer of vitamin B3. Since 1971 Lonza has supplied
more than half the world’s demand for vitamin B3 in the human and animal health
nutrition industries.

Lonza
acquires Arch Chemicals, Inc., a global biocides company providing innovative solutions
to destroy or to selectively inhibit the growth of harmful microorganisms, to create
the world’s leading microbial control business. The combined businesses will be
able to develop innovative microbial control formulations based on a broad portfolio
of registered and approved active ingredients.

Lonza Group Ltd (SIX stock code: LONN VX; SGX-ST stock code: O6Z) makes its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 21 October 2011 and consequently is the first SIX Swiss-listed company to dual list in Singapore.

Lonza to expand early-phase manufacturing capacity at its site in Nansha, China, to serve small molecules market.

2012

Lonza builds “Factory of Tomorrow” with investments in continuous flow and microreactor technology. The manufacturing concept offers increased flexibility and capacity for production that uses continuous flow and microreactor technologies and will be established at its Visp, Switzerland site.

Lonza signs definitive agreement for the sale of Brandenburg, KY (USA) Performance Urethanes and Organics business to Monument Chemical.

Lonza and Sartorius Stedim Biotech enter collaboration, supply and distribution agreement in the field of cell culture media, in which Sartorius Stedim Biotech assumes global sales and marketing of media and buffer solutions for biopharmaceutical manufacturing. Lonza will continue to manufacture all media products.

Lonza adapts its management structure to focus on
target markets and improve profitability. In
alignment with Lonza markets, the current Custom Manufacturing and Bioscience
sectors will be regrouped into one Pharma&Biotech segment.
Microbial Control and Life Science Ingredients will be regrouped into a
Specialty Ingredients segment.

Lonza awarded Contract to Generate Research Grade
iPSCs by the National Institutes of Health Center for Regenerative Medicine.

2014

Bristol-Myers Squibb and Lonza expand
manufacturing agreement. The contract expansion will include the production of
commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza’s
mammalian manufacturing facility in Portsmouth, NH (USA).

Lonza
signs exclusive agreement with Index Ventures for the development and manufacture
of biologics for portfolio companies.

Lonza
acquires Triangle Research Lab, a hepatocyte provider based in North Carolina (USA).

Lonza acquires InterHealth Nutraceuticals,
based in Benicia, CA (USA), which is a leader in research, development, manufacture
and marketing of proprietary, value-added nutritional ingredients for use in dietary
supplements.

2017

Lonza
and Sanofi enter into a strategic partnership to establish a large-scale biologics
production facility.

Lonza completes acquisition of Capsugel
to create leading integrated solutions provider to the global pharma and consumer
healthcare and nutrition industries.